Two Sigma Investments
DRMA icon

Two Sigma Investments’s Dermata Therapeutics DRMA Stock Holding History

Two Sigma Investments’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed -$33K – 3107
2021
Q4 		$33K Buy
+8
New +$70.7K ﹤0.01% 4161

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments's DRMA Position: Q1 2022 in Review

Two Sigma Investments sold out of Dermata Therapeutics (DRMA) in Q1 2022, closing a stake of 8 shares — an estimated $33K sold.

Two Sigma Investments first reported a position in DRMA in Q4 2021 and held it in 1 quarter. The position peaked at $33K in Q4 2021. 6 funds tracked by Wall St. Rank hold DRMA as of Q1 2022.

  • Two Sigma Investments reported no remaining Dermata Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Investments sold 8 Dermata Therapeutics shares in Q1 2022, an estimated $33K.
  • Two Sigma Investments first reported a position in Dermata Therapeutics in Q4 2021 and held it in 1 quarter.
  • Two Sigma Investments's Dermata Therapeutics position peaked at $33K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.